52 related articles for article (PubMed ID: 22629725)
1. Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.
Fan JG; Zhong L; Tia LY; Xu ZJ; Li MS; Wang GL
World J Gastroenterol; 2005 Apr; 11(15):2346-50. PubMed ID: 15818751
[TBL] [Abstract][Full Text] [Related]
2. The treatment with ursodeoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a case-control study.
Troisi G; Crisciotti F; Gianturco V; D'Ottavio E; Lo Iacono C; Formosa V; Bernardini S; Bellomo A; Marigliano B; Marigliano V
Clin Ter; 2013; 164(3):203-7. PubMed ID: 23868620
[TBL] [Abstract][Full Text] [Related]
3. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A
J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ursodeoxycholic acid in nonalcoholic fatty liver disease: An updated meta-analysis of randomized controlled trials.
Zhang W; Tang Y; Huang J; Hu H
Asia Pac J Clin Nutr; 2020; 29(4):696-705. PubMed ID: 33377363
[TBL] [Abstract][Full Text] [Related]
5. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression.
Gottlieb A; Canbay A
Cells; 2019 Oct; 8(11):. PubMed ID: 31671697
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients.
Mueller M; Castro RE; Thorell A; Marschall HU; Auer N; Herac M; Rodrigues CMP; Trauner M
Liver Int; 2018 Mar; 38(3):523-531. PubMed ID: 28853202
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid accelerates bile acid enterohepatic circulation.
Zhang Y; Jiang R; Zheng X; Lei S; Huang F; Xie G; Kwee S; Yu H; Farrar C; Sun B; Zhao A; Jia W
Br J Pharmacol; 2019 Aug; 176(16):2848-2863. PubMed ID: 31077342
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK.
Wu P; Zhao J; Guo Y; Yu Y; Wu X; Xiao H
Biochem Biophys Res Commun; 2020 Aug; 529(3):834-838. PubMed ID: 32595039
[TBL] [Abstract][Full Text] [Related]
9. Treatment of NASH with ursodeoxycholic acid: pro.
Ratziu V
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S41-5. PubMed ID: 23141893
[TBL] [Abstract][Full Text] [Related]
10. The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients.
Elhini SH; Wahsh EA; Elberry AA; El Ameen NF; Abdelfadil Saedii A; Refaie SM; Elsayed AA; Rabea HM
Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36558967
[TBL] [Abstract][Full Text] [Related]
11. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (9):125-31. PubMed ID: 22629789
[TBL] [Abstract][Full Text] [Related]
12. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
[TBL] [Abstract][Full Text] [Related]
13. Treatment of NASH with ursodeoxycholic acid: cons.
Liechti F; Dufour JF
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S46-52. PubMed ID: 23141894
[TBL] [Abstract][Full Text] [Related]
14. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
[TBL] [Abstract][Full Text] [Related]
15. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review.
Xiang Z; Chen YP; Ma KF; Ye YF; Zheng L; Yang YD; Li YM; Jin X
BMC Gastroenterol; 2013 Sep; 13():140. PubMed ID: 24053454
[TBL] [Abstract][Full Text] [Related]
16. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (11):79-85. PubMed ID: 22629725
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
